Abstract:Background Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension. Methods In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test. Results Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20±3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87±3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (±standard deviation) in the bimatoprost/timolol fixed combination group was (−9.38±4.66) mmHg and it was (−8.93±4.25) mmHg in the concurrent group (P <0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: −1.68, 0.57, P=0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P >0.05). Conclusions Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.

Intraocular Pressure-Lowering Effect of Tetrandrine and Timolol on Rats with Ocular Hypertension

Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension.

Clinical studies of D-timolol vs L-timolol

Timolol,brinzolamide and Travoprost in Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension

Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits.

Clinic Application of Timolol Ophthalmic Gel

A Meta-Analysis of Therapy Comparison Between Bimatoprost and Timolol in Ocular Hypertention Eye

Timolol maleate, a β blocker eye drop, improved edema in a retinal vein occlusion model

Efficacy and Safety of Travoprost Versus Timolol to Treat Early-Onset Ocular Hypertension Secondary to Vitrectomy: A Randomized Trial

Hypotensive activity of tetrandrine in rats. Investigation into its mode of action.

An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Hypotensive Activity of Tetrandrine in Rats

Protective effects of triptolide on retinal ganglion cells in a rat model of chronic glaucoma.

Safety and Efficacy of Bimatoprost/timolol Fixed Combination in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

[Study of Thioredoxin Antioxidative System in Lateral Geniculate Body of Chronic Intraocular Hypertension Rat].

Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.

Tetrandrine, an Alkaloid from S. Tetrandra Exhibits Anti-Hypertensive and Sleep-Enhancing Effects in SHR Via Different Mechanisms.

Tetrandrine, an Antihypertensive Alkaloid, Improves the Sleep State of Spontaneously Hypertensive Rats (Shrs).

Protective effect of triptolide on retinal ganglion cells in chronic ocular hypertension model

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.